Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Sangamo Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Sangamo Therapeutics, Inc.’s stock price such as:

• Sangamo Therapeutics, Inc.’s current stock price and volume
• Why Sangamo Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for SGMO from analysts
• SGMO’s stock price momentum as measured by its relative strength

About Sangamo Therapeutics, Inc. (SGMO)

Before we jump into Sangamo Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.

Want to learn more about Sangamo Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Sangamo Therapeutics, Inc..

What Caused Sangamo Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 28, 2025, there were 0 analysts who downgraded Sangamo Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Sangamo Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Sangamo Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Sangamo Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Sangamo Therapeutics, Inc. (SGMO) by visiting AAII Stock Evaluator.

Relative Price Strength of Sangamo Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 28, 2025, Sangamo Therapeutics, Inc. has a weighted four-quarter relative price strength of -27.90%, which translates to a Momentum Score of 5 and is considered to be Very Weak.

Want to learn more about how Sangamo Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Sangamo Therapeutics, Inc. Stock Price: Bottom Line

As of December 1, 2025, Sangamo Therapeutics, Inc.’s stock price is $0.425, which is down 7.72% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Sangamo Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.